# Pop Quiz #1

Standards 4.4 and 4.5

1. Surveillance measures are rated for compliance by the Commission on Cancer?
	1. True
	2. False
2. EPR stands for which of the following (select one):
3. Estimated Performance Range
4. Exact Performance Rate
5. Estimate Program Rate
6. Estimated Performance Rate
7. CP3R measures are available for all cancer sites?
	1. True
	2. False
8. If you modify a case in the CP3R database it will automatically update in your cancer registry database?
	1. True
	2. False
9. Programs only have to comply with CP3R measures during the survey year?
	1. True
	2. False

# Pop Quiz #2

Standard 4.6

1. Standard 4.6 Monitoring of Compliance with Evidence-Based Guidelines must be performed by the Cancer Liaison Physician?
	1. True
	2. False
2. A source of assessment must include the following:
3. Review of a single treatment regimen for a specific cancer site
4. A cancer site-specific sample
5. Either A or B
6. Both A and B
7. AJCC staging forms are a required part of the medical record?
	1. True
	2. False
8. Any problems identified with the diagnostic evaluation or treatment planning process may serve as a source for performance improvement?
	1. True
	2. False

# Pop Quiz #3

Standard 4.7

1. Study of Quality topics must be selected based on which of the following;
2. Your top cancer site in the last complete year
3. The site selected by the Chair or the Cancer Liaison Physician
4. One of the CP3R cancer sites being reviewed for accountability measures
5. A problematic quality-related issue relevant to the cancer program
6. None of the above
7. It is acceptable to utilize CP3R data reports to meet this standard?
	1. True
	2. False
8. The cancer program must design a corrective action plan based on the evaluation of the data?
	1. True
	2. Falswe
9. Studies of Quality must include multidisciplinary representation from which of the following;
10. Medical Oncology, Radiation Oncology and Surgery
11. Physicians, Nurses and Allied Health Professionals
12. The Quality Improvement Coordinator and the Cancer Committee Chair
13. Clinical, Administrative and Patient Perspectives
14. None of the above